Compare ACADIA Pharmaceuticals Inc. (ACAD) vs M&T Bank Corporation (MTB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs M&T Bank Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while M&T Bank Corporation trades at $234.39 (market cap $35.11B). The key difference: M&T Bank Corporation is far larger — about 7.8× ACADIA Pharmaceuticals Inc.'s market cap, and M&T Bank Corporation pays a 2.5% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MTB | |
|---|---|---|
Market Cap | $4.49B | $35.11B |
Sector | Health | Financials |
52-Week High | $28.06 | $241.95 |
52-Week Low | $20.06 | $178.63 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
MTB trades at $239.75, up 0.36% today, near the consensus price target of $241.56. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. Revenue grew to $9.63B in 2025, with a strong net income margin of 29.59%. Recent news highlights upcoming Q2 2026 earnings and strategic leadership appointments, reinforcing operational focus.
The outlook is cautiously positive, supported by solid fundamentals and analyst consensus, but risks include elevated investing cash outflows and sensitivity to interest rate changes. The stock presents a value opportunity with a reasonable P/E of 13.47, though investor sentiment remains mixed ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
